[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640867":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":56,"collaborators":37,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":37,"enrollmentInfo":68,"targetDuration":37,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":37,"overallStatus":44,"whyStopped":37,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Afimkibart Group I","EXPERIMENTAL","Participants will recieve Afimkibart as subcutaneous (SC) injection.",[13],"Drug: Afimkibart",{"label":15,"type":10,"description":16,"interventionNames":17},"Afimkibart Group II","Participants will receive Afimkibart as SC injection.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Afimkibart","Participants will receive Afimkibart as per the schedule mentioned in the protocol.",[9,15],[25,26,27],"PF-06480605","RVT-3101","RO7790121",[29],{"name":30,"affiliation":5,"role":31},"Clinical Trials","STUDY_DIRECTOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Reference Study ID Number: WA46440 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728",null,"global-roche-genentech-trials@gene.com",{"name":40,"role":35,"phone":37,"phoneExt":37,"email":37},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":37},"DM Clinical Research","RECRUITING","Tomball","Texas","77375","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-95.61605,30.09716,{"lat":54,"lon":53},{"type":57,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100640867","phase-2-an-extension-study-to-assess-long-term-safety-and-efficacy-of-afimkibart-in-participants-with-rheumatoid-arthritis-100640867",false,"NCT07620392","An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis","An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials","dRAvite-LTE","Inclusion Criteria:\n\n* Completed the treatment period of the parent study\n* Agreement to adhere to the contraception requirements\n* Continued to be evaluated at the follow-up visit of the parent study and achieved improvement in the SJC66\u002FTJC68 relative to baseline\n\nExclusion Criteria:\n\n* Withdrawal of consent and\u002For premature discontinuation from parent study\n* Any permanent discontinuation of study drug in parent study\n* Use of a prohibited therapy during the parent study\n* Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant participation in the trial","ALL","18 Years",{"count":69,"type":70},120,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and\u002For Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.",[76],"Rheumatoid Arthritis","2026-06-24",{"date":79,"type":80},"2026-06-26","ACTUAL",{"date":82,"type":80},"2026-06-03",{"date":84,"type":70},"2033-07-08",{"name":5,"class":6},1]